Publications by authors named "Hampig Raphael Kourie"

141 Publications

Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?

Future Oncol 2022 Jan 24. Epub 2022 Jan 24.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2021-1309DOI Listing
January 2022

BRAF: a biomarker not to be missed in glioblastoma.

Per Med 2022 Jan 21. Epub 2022 Jan 21.

Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2021-0118DOI Listing
January 2022

Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.

JCO Glob Oncol 2022 Jan;8:e2100153

Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Purpose: Fertility and pregnancy-related issues are highly relevant for young (≤ 40 years) patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of physicians from low- and middle-income countries (LMICs) regarding these issues.

Methods: A 19-item questionnaire adapted from an international survey exploring issues about fertility preservation and pregnancy after breast cancer was sent by e-mail between November 2019 and January 2020 to physicians from LMICs involved in breast cancer care. Descriptive analyses were performed.

Results: A total of 288 physicians from Asia, Africa, America, and Europe completed the survey. Median age was 38 years. Responders were mainly medical oncologists (44.4%) working in an academic setting (46.9%). Among responders, 40.2% and 53.8% reported having never consulted the available international guidelines on fertility preservation and pregnancy after breast cancer, respectively. 25.0%, 19.1%, and 24.3% of responders answered to be not at all knowledgeable about embryo, oocyte, or ovarian tissue cryopreservation, respectively; 29.2%, 23.6%, and 31.3% declared that embryo, oocyte, and ovarian tissue cryopreservation were not available in their countries, respectively. 57.6% of responders disagreed or were neutral on the statement that controlled ovarian stimulation can be considered safe in patients with breast cancer. 49.7% and 58.6% of responders agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence overall or only in those with hormone receptor-positive disease, respectively.

Conclusion: This survey showed suboptimal knowledge, practice, and attitudes of physicians from LMICs on fertility preservation and pregnancy after treatment completion in young women with breast cancer. Increasing awareness and education on these aspects are needed to improve adherence to available guidelines and to promote patients' oncofertility counseling.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO.21.00153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769103PMC
January 2022

HER2 in gastric adenocarcinoma: where do we stand today?

Per Med 2022 01 9;19(1):67-78. Epub 2021 Dec 9.

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, 17-5208, Lebanon.

 is a proto-oncogene expressed in 10-30% of gastric adenocarcinomas and is an ideal target for inhibition in malignancy with high recurrence and dismal survival rates. A systematic search was conducted via PubMed, Google Scholar and the clinicaltrials.gov database to report the results of ongoing and past studies investigating HER2 inhibitors in gastric cancer. Twenty-five studies were included; ToGA trial is the pivotal trial approving the use of trastuzumab in metastatic gastric cancer, followed by more studies investigating other HER2 inhibitors in this setting, as well as in local and locoregional malignancy. Anti-HER2 molecules are proving efficacy and safety in gastric cancer; the evidence is growing and association with other cancer agents is under investigation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2021-0004DOI Listing
January 2022

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.

Crit Rev Oncol Hematol 2021 Dec 17;168:103524. Epub 2021 Nov 17.

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

RAS is the most frequently mutated oncogene in human cancer. Scientists attempted for decades to target this protein or its pathways, however, all the attempts failed and RAS was labeled as "undruggable". With KRAS-G12C covalent inhibitors entering clinical trials, the myth of this "undruggable" RAS is fading away. In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced or metastatic NSCLC, following at least one prior systemic therapy. However, and as every other drug, KRAS-G12C inhibitors are facing intrinsic and acquired resistances. In order to overcome these resistances, researchers are now working on combination strategies. Furthermore, studies are currently ongoing to better elucidate the status of KRAS-G12C as a predictive and prognostic tool and to strengthen its role in the field of personalized medicine.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2021.103524DOI Listing
December 2021

Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.

Pharmacogenomics 2021 12 3;22(18):1237-1250. Epub 2021 Nov 3.

Hematology & Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Poly-(ADP-ribose) polymerase (PARP) inhibitors act in cells with defects in homologous recombination DNA repair (HRR) caused by genomic aberrations such as mutations. This phenomenon called synthetic lethality is known now to be more common in prostate cancer than previously thought. Olaparib and rucaparib, two PARP inhibitors, were successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer. They received a breakthrough US FDA approval in HRR altered metastatic castration-resistant prostate cancer in May 2020. Consequently, the combination of PARP inhibitors with other agents such as androgen receptor pathway inhibitors, immune checkpoint inhibitors or DNA damage inducing chemotherapy are being currently largely studied. In our review, we aim to summarize the key PARP inhibitors published and ongoing trials in prostate cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2021-0119DOI Listing
December 2021

After decades, RAS mutation has finally become a therapeutic target.

Per Med 2021 09 18;18(6):523-525. Epub 2021 Oct 18.

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2021-0015DOI Listing
September 2021

Molecular pathogenesis of hereditary lung cancer: a literature review.

Pharmacogenomics 2021 08 19;22(12):791-803. Epub 2021 Aug 19.

Pulmonary & Critical Care Division, Hotel Dieu de France, Saint Joseph University of Beirut, Beirut, Lebanon.

Among all cancer types, pulmonary cancer has the highest mortality rate. Tobacco consumption remains the major risk factor for the development of lung cancer. However, many studies revealed a correlation between inherited genetic variants and predisposition to lung cancer, especially in nonsmokers. To date, genetic testing for the detection of germline mutations is not yet recommended in patients with lung cancer and testing is focused on somatic alterations given their implication in the treatment choice. Understanding the impact of genetic predisposition on the occurrence of lung cancer is essential to enable the introduction of accurate guidelines and recommendations that might reduce mortality. In this review paper, we describe familial lung cancer, and expose germline mutations that are linked to this type of cancer. We also report pathogenic genetic variants linked to syndromes associated with lung cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2020-0150DOI Listing
August 2021

Molecular profiling of basal cell carcinomas in young patients.

BMC Med Genomics 2021 07 20;14(1):187. Epub 2021 Jul 20.

Dermatology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Background: Basal cell carcinoma (BCC) represents by far the most common non-melanoma skin cancer (NMSC) in the world with an increasing incidence of 3% to 10% per year, especially in patients under the age of 40. While variants in the sonic Hedgehog and cell cycle regulation pathways account for the majority of BCC cases in adults, the molecular etiology of BCC in young patients is unelucidated yet. This study aims to investigate the molecular profile of BCC in the young population.

Methods: 28 tumors belonging to 25 Lebanese patients under the age of 40, presenting different stages of BCC and diagnosed at Hôtel Dieu de France-Saint Joseph University Medical Center were included in this study. A selected panel of 150 genes involved in cancer was analyzed by Next Generation Sequencing (NGS) in the 28 included tumors.

Results: Genetic variants detected in more than 5% of the reads, with a sequencing depth ≥ 50x, were selected. Two hundred and two genetic variants in 48 different genes were detected, with an overall average sequencing depth of 1069x. Among the 28 studied tumors, 18 (64.3%) show variations in the PTCH1 gene, 6 (21.4%) in TP53 and 3 (10.7%) in SMO.

Conclusions: This is the first study reporting NGS-based analysis of BCC in a cohort of young patients. Our results highlight the involvement of the hedgehog and cell cycle regulation pathways in the genesis of BCC in the general population. The inclusion of a larger cohort of young patients is needed to confirm our findings.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-021-01030-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293576PMC
July 2021

YouTube as a source of information on breast cancer in the Arab world.

Support Care Cancer 2021 Dec 5;29(12):8009-8017. Epub 2021 Jul 5.

Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.

Background: The general population is increasingly using YouTube as a source of information on breast cancer, the most frequent cancer among women. Arabs are the most interested population in breast cancer on YouTube. The transmission of accurate information is important to reduce mortality rates. This cross-sectional study aims to evaluate breast cancer videos on YouTube in the Arab world.

Methods: A YouTube search for "breast cancer" in Arabic was performed. The most viewed 60 videos included were evaluated for global quality (GQS score), reliability (modified DISCERN score), content (content score), and misleading claims. Recorded and calculated data included views, duration, videos power index, and viewers' interaction. Sources from legal persons (governments, universities, TV channels, physicians' groups), and blogs (online health channels, individuals) were categorized.

Results: The median global quality (3/5), reliability (2/5), and content scores (4/11) were overall low. Misleading information was found in 42% of the videos. Although videos uploaded by legal persons were less popular (163,454 vs 327,488 views), they hosted more physicians (52% vs 15%), were less misleading (15% vs 64%), covered more content, and were of higher global quality and reliability than videos uploaded by blogs [p < 0.05]. While the topic of symptoms (55%) was discussed the most, genetic counseling (13%) and prevention (20%) were the least mentioned.

Conclusions: YouTube is poorly informational and inaccurate on breast cancer in the Arab World where it is highly used. Although videos uploaded by legal persons tend to be more adequate, they are of lower popularity. Governments and physicians are encouraged to upload more intelligibly informational videos, guide the population to reliable sources, and support regulations.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-021-06403-6DOI Listing
December 2021

PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare.

Immunotherapy 2021 08 30;13(12):1053-1065. Epub 2021 Jun 30.

Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.

PD-L1 is an important predictive biomarker for treatment by immune checkpoint inhibitors (ICIs). ICIs are now indicated for the treatment of various cancer depending on the level of expression of PD-L1 on tumor cells. PD-L1 testing is done using immunohistochemistry with five different assays approved as companion diagnostic for ICIs. However, these assays have different score reporting methods and do not accurately measure PD-L1 expression. Exosomal PD-L1 testing has recently emerged as an alternative for cell-surface PD-L1 testing however studies are still premature and more extensive knowledge about this new potential biomarker is needed.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2020-0336DOI Listing
August 2021

Urothelial carcinoma in the era of immune checkpoint inhibitors.

Immunotherapy 2021 08 29;13(11):953-964. Epub 2021 Jun 29.

Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

Bladder cancer is the seventh most frequent cancer worldwide. The majority of patients present with nonmuscle invasive disease, while 20% of the patients are diagnosed with muscle-invasive bladder cancer. The treatment of nonmuscle invasive disease is endoscopic resection followed by intravesical adjuvant treatment for high risk patients. The standard treatment of localized muscle-invasive disease is neoadjuvant chemotherapy followed by radical cystectomy. Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma as second-line treatment or first-line in platinum-ineligible patients. Recently, pembrolizumab have been approved in bacillus Calmette-Guérin (BCG)-refractory nonmuscle invasive bladder cancer. This review summarizes the current evidence concerning immunotherapy in the treatment of urothelial carcinoma.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2021-0042DOI Listing
August 2021

KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

Pharmacogenomics 2021 07 21;22(10):587-590. Epub 2021 Jun 21.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2021-0045DOI Listing
July 2021

First advanced course on biomarkers in molecular and immuno-oncology in the Middle East.

Future Oncol 2021 Aug 21;17(22):2831-2834. Epub 2021 Jun 21.

Department of Hematology & Oncology, Hotel Dieu de France University Hospital, 166830, Beirut, Lebanon.

The first 'advanced course on biomarkers in molecular and immuno-oncology' in the Middle East took place in Beirut, Lebanon, as a hybrid meeting on 11 December 2020. The aim of this seminar was to discuss biomarker development, implications and detection modalities and to highlight advances in molecular technologies as well as the clinical applicability of biomarkers in oncology. The seminar consisted of five sessions, each discussing a special topic in the biomarker field. It also included a competition in the form of a quiz following each session. This was followed by a plenary session presented by well-known national and international speakers, highlighting various aspects of biomarkers in immuno-oncology.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2021-0192DOI Listing
August 2021

Targeting in -positive breast cancer: what are the opportunities and the challenges?

Biomark Med 2021 06;15(9):609-613

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm-2021-0236DOI Listing
June 2021

Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?

Pharmacogenomics 2021 07 28;22(10):619-628. Epub 2021 May 28.

Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Bladder cancer (BC) is the most common cancer involving the urinary system and the ninth most common cancer worldwide. Tobacco smoking is the most important environmental risk factor of BC. Several single nucleotide polymorphisms have been validated by genome-wide association studies as genetic risk factors for BC. However, the identification of DNA mismatch-repair genes, including in Lynch syndrome and in -associated polyposis, raises the possibility of monogenic hereditary forms of BC. Moreover, other genetic mutations may play a key role in familial and hereditary transmissions of BC. Therefore, the aim of this review is to focus on the major hereditary syndromes involved in the development of BC and to report BC genetic susceptibilities established with genome-wide significance level.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2020-0165DOI Listing
July 2021

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib.

Leuk Res Rep 2021 11;15:100245. Epub 2021 May 11.

Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia. Chromosomal abnormalities are reported to play important roles in CLL pathogenesis and evolution, including deletions of 11q, 13q, 17p, and trisomy12, that are frequently observed and have a known prognostic value. Furthermore, the mutational status of the gene was reported as an independent prognostic marker in CLL impacting the choice of therapy. We herein, report an unusual presentation of a Lebanese CLL patient with two cytogenetic abnormalities: trisomy 12 and t(14;18)(q32;q21), along with an unmutated , displaying a favorable response to ibrutinib with a maintained complete remission.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lrr.2021.100245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141474PMC
May 2021

Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.

Pharmacogenomics 2021 04 23;22(5):247-250. Epub 2021 Mar 23.

Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2021-0002DOI Listing
April 2021

Cancer management during the COVID-19 pandemic: Choosing between the devil and the deep blue sea.

Crit Rev Oncol Hematol 2021 Nov 15;167:103273. Epub 2021 Mar 15.

Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Beirut, Lebanon.

COVID-19 was declared a "Public Health Emergency of International Concern" in March 2020. Since then, drastic measures were implemented to reduce the virus spread. These measures prevented cancer patients from receiving prompt medical care. A delay in testing and treating cancer patients is thought to protect them from serious COVID-19 complications but exposes them at the same time to the risk of disease progression and cancer related mortality. Healthcare providers are therefore facing the dilemma of choosing between two unpleasant scenarios. To shed light upon the matter, we present in this review article, based on an extensive search of the literature, an overview of the delay in the management of cancer patients, possible contributors to this delay and its benefits and risks on cancer patients' health.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2021.103273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959683PMC
November 2021

Targeting glioblastoma: from dream to reality.

Biomark Med 2021 04 12;15(6):385-388. Epub 2021 Mar 12.

Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm-2021-0113DOI Listing
April 2021

Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?

Immunotherapy 2021 04 9;13(6):459-463. Epub 2021 Feb 9.

Department of Urology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2020-0285DOI Listing
April 2021

Will advanced cholangiocarcinoma become a targetable malignancy?

Crit Rev Oncol Hematol 2021 Mar 19;159:103233. Epub 2021 Jan 19.

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

Cholangiocarcinoma and biliary tract cancers are rare but aggressive tumors that are characterized by an heterogenous molecular and genetic footprint. Genetic aberrations such as FGFR2 fusion and ErBb2 amplification are common in those cancers. Recent studies aimed at exploring the efficacy and benefit of targeted therapy in the treatment of advanced cholangiocarcinoma. Many promising drugs exist and warrant additional investigations. This review will summarize available results and highlight therapeutic strategies incorporated in clinical trials.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2021.103233DOI Listing
March 2021

Cancer Patients in the Era of Coronavirus: What to Fear Most?

J Patient Saf 2021 01;17(1):e35-e38

From the Departments of Hematology-Oncology.

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to a worldwide medical crisis, affecting mostly immunocompromised patients, such as cancer patients. Various cancer societies have issued recommendations regarding patients care, but few studies addressed the perception of cancer patients regarding this pandemic.

Objective: The aim of the study was to assess the perception of cancer patients regarding their health risks during this pandemic and the preventive measures taken.

Materials And Methods: An anonymous survey was conducted among cancer patients presenting for their treatment, during 10 consecutive working days, at the one-day clinic of Hotel-Dieu de France University hospital in Beirut. We evaluated their state of disease, comorbidities, precautions taken, and their concerns regarding the virus spread.

Results: A total of 216 patients responded with a mean age of 60 years. The majority had a good performance status (performance status = 0-1 in 79.6%), 51.4% had metastatic disease, and chemotherapy was the main therapy used (65.7%). A total of 52.3% of patients considered themselves to be at increased risk of contracting the virus. A total of 55.1% were more worried about the coronavirus rather than their disease. The priority was for the treatment of their cancer in 47.7% of the total patients studied. Of note, only 2.8% of planned one-day clinic reservations were canceled or postponed to avoid COVID-19 exposure.

Conclusions: Although cancer is a disease with a high mortality rate, many patients are more concerned about the actual pandemic rather than their disease. Nevertheless, the absenteeism from their treatment sessions during the COVID-19 atmosphere was minimal.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/PTS.0000000000000797DOI Listing
January 2021

Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care?

Future Oncol 2021 Jan 11;17(3):229-233. Epub 2020 Dec 11.

Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, 166830, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0836DOI Listing
January 2021

Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature.

Crit Rev Oncol Hematol 2021 Jan 22;157:103169. Epub 2020 Nov 22.

Department of Nephrology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Targeting the immune system with immune checkpoint inhibitors (ICI) to treat cancer has been lately adopted with a significant improvement of patients' survival. In parallel, the incidence of malignancy in chronic kidney disease (CKD) patients is increasing, but solid evidence concerning the efficacy and safety of ICI in this population is lacking. Moreover, the use of these agents as immunity boosters in kidney graft recipients treated with immunosuppressors is still controversial. We present in this article a review of the pharmacological properties of these drugs and their behavior with kidney failure and dialysis, as well as evidence of their use in different populations of CKD. Most of the available data are limited to case reports and case series. These drugs appear to be safe without dose adjustment in CKD patients and patients on dialysis. A major concern with this therapy in transplanted patients remains the risk of graft rejection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.103169DOI Listing
January 2021

In reply to: incorporating teleoncology practices in the undergraduate medical curriculum.

Future Oncol 2021 01 27;17(1):11-12. Epub 2020 Nov 27.

Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Riad El Solh, 11-5076, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720648PMC
January 2021

Diagnosis and treatment of lymphomas in the era of epigenetics.

Blood Rev 2021 07 17;48:100782. Epub 2020 Nov 17.

Bordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, F-33000 Bordeaux, France. Electronic address:

Lymphomas represent a heterogeneous group of cancers characterized by clonal lymphoproliferation. Over the past decades, frequent epigenetic dysregulations have been identified in hematologic malignancies including lymphomas. Many of these impairments occur in genes with established roles and well-known functions in the regulation and maintenance of the epigenome. In hematopoietic cells, these dysfunctions can result in abnormal DNA methylation, erroneous chromatin state and/or altered miRNA expression, affecting many different cellular functions. Nowadays, it is evident that epigenetic dysregulations in lymphoid neoplasms are mainly caused by genetic alterations in genes encoding for enzymes responsible for histone or chromatin modifications. We summarize herein the recent epigenetic modifiers findings in lymphomas. We focus also on the most commonly mutated epigenetic regulators and emphasize on actual epigenetic therapies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2020.100782DOI Listing
July 2021

Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK.

Per Med 2021 01 30;18(1):5-7. Epub 2020 Oct 30.

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2020-0036DOI Listing
January 2021

Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas.

Immunotherapy 2020 11 20;12(16):1149-1152. Epub 2020 Oct 20.

Ophtalmology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2020-0234DOI Listing
November 2020

The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon.

Complement Ther Med 2020 Sep 12;53:102534. Epub 2020 Aug 12.

Hematology and Oncology department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Introduction: Medical hypnosis has received an increasing attention during the past decades. Various applications of hypnosis can be incorporated into the oncology field. This study aims to assess the knowledge of Lebanese medical oncologists on the use of hypnosis in the management of cancer patients.

Material And Methods: An anonymous questionnaire was sent to all Lebanese medical oncologists to assess their knowledge, opinion and understanding of hypnosis and its use in oncology, as well as the obstacles facing its application in Lebanon.

Results: Hundred and three Lebanese medical oncologists responded to the survey, with a response rate of 65%. The findings revealed that most oncologists had little or no knowledge about hypnosis, but recommended it due to the benefits they believed it provided for the patients in improving chronic pain, invasive procedures, chemotherapy-induced nausea and anxiety. Around 40% of participants were interested in receiving a training in hypnosis. Lebanese oncologists also described many obstacles to the practice of hypnosis, mainly the lack of training for this technique and the lack of financial resources.

Conclusion: Despite all obstacles, the majority of Lebanese oncologists would recommend hypnosis to their patients in order to improve their quality of life.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctim.2020.102534DOI Listing
September 2020
-->